Facente Consulting is providing training and technical assistance to grant recipients of the Gilead Oncology Corporate Giving Program to support them in evaluating the impact of programs on improving outcomes and health equity among people affected by cancer.
Project Descriptions
Evaluation Training and Technical Assistance for Oncology Programs
Statistical Support for an Advanced HIV Prevention Clinical Trial Design
Gilead Sciences
Facente Consulting supported Gilead Sciences with statistical analysis relating to HIV incidence rates, assisting with the study design, analysis plan, and interpretation of study data for the PURPOSE trials–ultimately leading to the groundbreaking FDA approval of the twice-yearly PrEP medication Lenacapavir.